[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368628-105":59,"doc-detail-368628-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","toward-pharmacologic-therapy-for-glioblastoma-identifying-inhibitors-of-very-long-chain-acyl-coa-synthetase-3-acsvl3","Toward pharmacologic therapy for glioblastoma - Identifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3)","","Brain tumors, especially glioblastoma multiforme (GBM), are aggressive and difficult to treat, with a ~7% 5-year survival rate despite surgery, radiation, and chemotherapy. The study identifies very long-chain acyl-CoA synthetase 3 (ACSVL3) as overproduced in glioma tissue and U87MG cells, where ACSVL3 depletion reduced tumorigenicity in nude mice. The work screens small molecules to inhibit ACSVL3 activity, measuring stearoyl-CoA formation and using ACSVL1/3 chimeric uptake assays with a fluorescent fatty acid analog. Compounds including CB5 and CB16.2 showed the strongest potency and the assay supports viable inhibitor discovery.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/toward-pharmacologic-therapy-for-glioblastoma-identifying-inhibitors-of-very-long-chain-acyl-coa-synthetase-3-acsvl3/368628/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/toward-pharmacologic-therapy-for-glioblastoma-identifying-inhibitors-of-very-long-chain-acyl-coa-synthetase-3-acsvl3/368628.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why target ACSVL3 for glioblastoma therapy?","Question",{"text":112,"@type":113},"ACSVL3 is overproduced in human glioma tissue and glioblastoma cell lines such as U87MG. Depleting ACSVL3 slows growth and reduces tumor formation in mice, suggesting therapeutic value if selective inhibitors are found.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study measure inhibition of ACSVL3 activity?",{"text":117,"@type":113},"The researchers used assays that quantify stearoyl-CoA formation from the stearic acid substrate, comparing effects in U87MG cells and ACSVL3-deficient U87-KO cells to assess ACSVL3-specific inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the two screening strategies used to identify inhibitors?",{"text":121,"@type":113},"First, the team tested compounds known to inhibit the related enzyme ACSVL1 and other library compounds for reduced stearoyl-CoA formation. Second, they developed a high-throughput assay using ACSVL1/3 chimeric proteins to couple drug effects to fluorescent fatty acid uptake.",{"name":123,"@type":110,"acceptedAnswer":124},"Which compounds showed the greatest potency in the primary screening?",{"text":125,"@type":113},"At 80 μM, CB5 and CB16.2 showed the greatest potency to inhibit ACSVL3 enzyme activity. At 10 μM, CB5 still showed significant inhibition while CB16.2 did not.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368628,1790196304,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","bioRxiv preprint doi: [https://doi.org/10.1101/2025.07.02.662811](https://doi.org/10.1101/2025.07.02.662811); this version posted July 3, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nToward pharmacologic therapy for glioblastoma:  \nIdentifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3)  \nEmily M. Clay* 1,2, Xiaohai Shi* 1,2, Elizabeth A. Kolar 1,2 Mayur Mody1, John E. Locke 1 and Paul A.  \nWatkins 1,2  \n*These authors contributed equally to this work  \n1Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205  \n2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205  \nPlease address correspondence to:  \nPaulA. Watkins MD, PhD  \nKennedy Krieger Institute  \n707 N. Broadway  \nBaltimore, MD 21205 USA  \n1-443-923-2754 (phone)  \n1-443-923-2755 (fax)  \n[watkins@kennedykrieger.org](watkins@kennedykrieger.org)  \nbioRxiv preprint doi: [https://doi.org/10.1101/2025.07.02.662811](https://doi.org/10.1101/2025.07.02.662811); this version posted July 3, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nABSTRACT  \nBrain tumors, in particular glioblastoma multiforme (GBM), are among the most aggressive and difficult to treat human neoplasms. Even with combined surgery, radiation and chemotherapy, the 5-year survival rate for GBM is only ~7% . Thus, new treatment approaches are needed. We previously found that the fatty acid metabolism enzyme “very long-chain acyl-CoA synthetase 3”(ACSVL3) is overproduced in human glioma tissue and in glioblastoma cell lines such as U87MG cells. These cells exhibited malignant growth properties in culture and were tumorigenic in nude mice. When either knockdown or knockout strategies were used to deplete U87MG cells ofACSVL3, they adopted a more normal growth rate and produced significantly fewer, slower growing tumors in mice. An inhibitor of ACSVL3, if identified, could prove to be a valuable pharmacotherapeutic agent in GBM. Therefore, we sought to identify small molecule compounds that decrease or block the enzyme activity of ACSVL3, as measured by the formation of stearoyl-CoA from the 18-carbon saturated fatty acid stearic acid, a preferred substrate forACSVL3 . We approached this in two ways. First, we tested several compounds that were previously shown to inhibit the activity of a structurally and functionally related enzyme, ACSVL1 . Several compounds tested showed inhibition of stearoyl-CoA formation in U87MG cells when added to an in vitro enzyme assay. These included drugs triflupromazine, phenazopyridine, chlorpromazine, emodin, and perphenazine which are approved for treating other conditions. Also inhibitory to stearoyl-CoA production were several compounds from a ChemBridge Corporation library designated CB2, CB5, CB6 and CB 16.2. One caveat regarding interpretation of these results is that in addition to ACSVL3, all cells including U87MG contain other acyl-CoA synthetases capable of using stearic acid as substrate. Therefore, we also measured stearoyl-CoA synthetase activity in ACSVL3-deficient U87MG cells (U87-KO) . If a drug or compound is an ACSVL3 inhibitor, it should decrease total conversion of stearate to stearoyl-CoA more in U87MG than in U87-KO cells. By this criterion, most of the tested compounds showed some ACSVL3-specific inhibition. At the screening concentration of 80μM drug, CB5 and CB16.2 showed the greatest potency to inhibit ACSVL3 enzyme activity; at 10 μM, CB5 still showed significant inhibition but CB16.2 did not. We conclude that these compounds are worthy of further investigation as potential therapeutic age","cbCaiuVPZhImt2gQ","https://ap.wps.com/l/cbCaiuVPZhImt2gQ","pdf",468218,26,"English","# Abstract\n## Rationale and role of ACSVL3 in GBM\n## Strategy 1: small-molecule inhibition assays\n## Strategy 2: high-throughput screening with ACSVL1/3 chimeras\n## Screening outcomes and conclusions","[{\"question\":\"Why target ACSVL3 for glioblastoma therapy?\",\"answer\":\"ACSVL3 is overproduced in human glioma tissue and glioblastoma cell lines such as U87MG. Depleting ACSVL3 slows growth and reduces tumor formation in mice, suggesting therapeutic value if selective inhibitors are found.\"},{\"question\":\"How did the study measure inhibition of ACSVL3 activity?\",\"answer\":\"The researchers used assays that quantify stearoyl-CoA formation from the stearic acid substrate, comparing effects in U87MG cells and ACSVL3-deficient U87-KO cells to assess ACSVL3-specific inhibition.\"},{\"question\":\"What were the two screening strategies used to identify inhibitors?\",\"answer\":\"First, the team tested compounds known to inhibit the related enzyme ACSVL1 and other library compounds for reduced stearoyl-CoA formation. Second, they developed a high-throughput assay using ACSVL1/3 chimeric proteins to couple drug effects to fluorescent fatty acid uptake.\"},{\"question\":\"Which compounds showed the greatest potency in the primary screening?\",\"answer\":\"At 80 μM, CB5 and CB16.2 showed the greatest potency to inhibit ACSVL3 enzyme activity. At 10 μM, CB5 still showed significant inhibition while CB16.2 did not.\"}]","Toward pharmacologic therapy for glioblastoma - Identifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3) | PDF",1790177780,66,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a87eab37cff5e1c0bddeccc7695da728.webp",983,1272,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0e41379bc929e9feb453df195fcd23b.webp",982,1270,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ead0b52b2bd561b45f73492040441bb9.webp",981,1269,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71a2d626b77056f09eb31eb921a2fb22.webp",980,1268]